Abdullah Al Sawaf, MD

Abdullah Al Sawaf, MD

Associate Professor
Neuroscience Institute
Languages:
English, Arabic

    About me

    Dr. Abdullah Al Sawaf is an Associate Professor in the Department of Neurology at Southern Illinois University School of Medicine.  He is a neurologist who specializes in epilepsy and seizure disorders. 

    Dr. Al Sawaf earned his medical degree at The University of Jordan in Amman, Jordan.  He completed his residency in neurology at the University of Kentucky Medical Center in Lexington, Kentucky.  He also completed his internship at the University of Kentucky Medical Center in Lexington, Kentucky.  He then completed a fellowship in neurophysiology/epilepsy at University of Vanderbilt Medical Center in Nashville, Tennessee.

    Dr. Al Sawaf is certified by the American Board of Psychiatry and Neurology (ABPN) and is eligible for certification in epilepsy, a subspecialty of the ABPN.  He is a member of numerous professional organizations including the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society.

    Gender

    Male

    Additional languages spoken

    Arabic

    Education & training

    Positions
    Neurologist
    Epilepsy Specialist
    Board Certifications
    Neurology
    Psychiatry
    Medical School
    Neurophysiology/Epilepsy Fellowship - University of Vanderbilt Medical Center, Nashville, Tennessee
    Residency
    University of Kentucky Medical Center, Lexington, KY - Neurology
    Fellowship
    Neurophysiology/Epilepsy Fellowship - University of Vanderbilt Medical Center, Nashville, Tennessee

    Clinical trials

    Trial
    Neurology

    A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    Active recruiting

    The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

    Active recruiting

    The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

    Active recruiting

    The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

    Contact: Rylee Manka 217-545-1394
    Trial
    Neurology

    A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

    Active recruiting

    The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

    Contact: Rylee Manka 217-545-1394
    Trial
    Neurology

    Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

    Active not recruiting

    This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

    Contact: Rylee Manka 217-545-1394